ReviewVascular health and risk management2009
Review of inhaled iloprost for the control of pulmonary artery hypertension in children.
Review in Vascular health and risk management, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 48 citations in OpenAlex.
- Safety and tolerability of continuous inhaled iloprost in critically ill pediatric pulmonary hypertension patients: A retrospective case series.Pulmonary circulation · 2023Article
- Design and Comprehensive Characterization of Tetramethylpyrazine (TMP) for Targeted Lung Delivery as Inhalation Aerosols in Pulmonary Hypertension (PH): In Vitro Human Lung Cell Culture and In Vivo Efficacy.Antioxidants (Basel, Switzerland) · 2021Article
- Drug Treatment of Pulmonary Hypertension in Children.Paediatric drugs · 2020Review
- Paediatric pulmonary arterial hypertension: updates on definition, classification, diagnostics and management.The European respiratory journal · 2019Review
- Inhaled combination of sildenafil and rosiglitazone improves pulmonary hemodynamics, cardiac function, and arterial remodeling.American journal of physiology. Lung cellular and molecular physiology · 2019Article
- Acute Effect of Inhaled Iloprost in Children with Pulmonary Arterial Hypertension Associated with Simple Congenital Heart Defects.Pediatric cardiology · 2018Article
- Administration of Inhaled Pulmonary Vasodilators to the Mechanically Ventilated Neonatal Patient.Paediatric drugs · 2017Review
- Iloprost drug delivery during infant conventional and high-frequency oscillatory ventilation.Pulmonary circulation · 2016Article
- Use of inhaled iloprost for the management of postoperative pulmonary hypertension in congenital heart surgery patients: review of a transition protocol.Pediatric cardiology · 2014Article
- Drug treatment of pulmonary hypertension in children.Paediatric drugs · 2014Review
- Current challenges in pediatric pulmonary hypertension.Seminars in respiratory and critical care medicine · 2013Review
- Pharmacotherapy for pulmonary hypertension.Pediatric clinics of North America · 2012Review
- Advances in pediatric pulmonary arterial hypertension.Current opinion in cardiology · 2012Review
- Medical therapy for pediatric pulmonary arterial hypertension.The Journal of pediatrics · 2010Article
- A New Era in Medical Management of Severe Pediatric Pulmonary Arterial Hypertension.Nihon Shoni Junkanki Gakkai zasshi = Pediatric cardiology and cardiac surgery · 2010Article
- Inhaled epoprostenol therapy for pulmonary hypertension: Improves oxygenation index more consistently in neonates than in older children.Pulmonary circulationArticle
- Current and emerging pharmacotherapies for the treatment of pulmonary arterial hypertension in infants.Expert opinion on pharmacotherapyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In the pediatric population, pulmonary hypertension may present as an acute event in the setting of lung or cardiac pathology or as a chronic disease, mainly as idiopathic pulmonary hypertension or associated with congenital heart disease. Recently, new pharmacologic approaches have demonstrated significant efficacy in the management of adults with pulmonary arterial hypertension; these include intravenous epoprostenol, prostacyclin analogs, endothelin receptor antagonists and phosphodiesterase type 5 inhibitors. The same treatment strategies are currently used in children. There are only few reports of the use of inhaled iloprost in pediatrics, only one of which reported the use of chronic inhaled iloprost in a significant number of children. This report showed that 1) the acute pulmonary vasodilator response to inhaled iloprost is equivalent to that of inhaled nitric oxide; 2) acute inhalation of iloprost can induce bronchoconstriction 3) the addition of inhaled iloprost can reduce the need for intravenous prostanoid therapy in some patients; 4) most children tolerated the combination of inhaled iloprost and endothelin receptor antagonist or phosphodiesterase inhibitors; 5) Several patients had clinical deterioration during chronic inhaled iloprost therapy and required rescue therapy with intravenous prostanoids. In this review we will discuss the role of inhaled iloprost in acute and chronic pulmonary hypertension in children.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.